Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer
Más información
Año de Inicio/Término: | Noviembre 2024 |
URL: | https://doi.org/10.1016/j.ygyno.2024.07.020 |
DOI: |
10.1016/j.ygyno.2024.07.020 |